Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.

Toshiki MasuishiAkihito TsujiMasahito KotakaMasato NakamuraMitsugu KochiAkinori TakaganeKen ShimadaTadamichi DendaYoshihiko SegawaHiroaki TaniokaHiroki HaraTamotsu SagawaTakanori WatanabeTakao TakahashiYuji NegoroDai ManakaHideto FujitaTakeshi SutoMasahiro TakeuchiWataru IchikawaMasashi Fujii

Published in: British journal of cancer (2020)

UMIN000010638.

Keyphrases

wild type
metastatic colorectal cancer
open label
clinical trial
placebo controlled